Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Increased risk of suicide in schizophrenia patients with linkage to chromosome 13q.

Malherbe PJ, Karayiorgou M, Ehlers R, Roos JL.

Psychiatry Res. 2017 May;251:34-35. doi: 10.1016/j.psychres.2017.02.008. Epub 2017 Feb 5.

PMID:
28189075
2.

The positive allosteric GABAB receptor modulator rac-BHFF enhances baclofen-mediated analgesia in neuropathic mice.

Zemoura K, Ralvenius WT, Malherbe P, Benke D.

Neuropharmacology. 2016 Sep;108:172-8. doi: 10.1016/j.neuropharm.2016.04.028. Epub 2016 Apr 22.

PMID:
27108932
3.

Phenotypic features of patients with schizophrenia carrying de novo gene mutations: a pilot study.

Malherbe PJ, Roos JL Jr, Ehlers R, Karayiorgou M, Roos JL.

Psychiatry Res. 2015 Jan 30;225(1-2):108-114. doi: 10.1016/j.psychres.2014.10.024. Epub 2014 Nov 6.

PMID:
25467704
4.

Inhibition of alcohol self-administration by positive allosteric modulators of the GABAB receptor in rats: lack of tolerance and potentiation of baclofen.

Maccioni P, Vargiolu D, Thomas AW, Malherbe P, Mugnaini C, Corelli F, Leite-Morris KA, Gessa GL, Colombo G.

Psychopharmacology (Berl). 2015 May;232(10):1831-41. doi: 10.1007/s00213-014-3815-8. Epub 2014 Nov 26.

PMID:
25420609
5.

Mapping the binding pocket of a novel, high-affinity, slow dissociating tachykinin NK3 receptor antagonist: biochemical and electrophysiological characterization.

Malherbe P, Knoflach F, Marcuz A, Bohnert C, Weber M, Knust H, Ratni H, Spooren W, Ballard TM, Bissantz C.

Neuropharmacology. 2014 Nov;86:259-72. doi: 10.1016/j.neuropharm.2014.07.017. Epub 2014 Aug 5.

PMID:
25107588
6.

Positive allosteric modulation of GABAB receptors ameliorates sensorimotor gating in rodent models.

Frau R, Bini V, Pillolla G, Malherbe P, Pardu A, Thomas AW, Devoto P, Bortolato M.

CNS Neurosci Ther. 2014 Jul;20(7):679-84. doi: 10.1111/cns.12261. Epub 2014 Apr 7.

7.

Reduction of alcohol intake by the positive allosteric modulator of the GABA(B) receptor, rac-BHFF, in alcohol-preferring rats.

Loi B, Maccioni P, Lobina C, Carai MA, Gessa GL, Thomas AW, Malherbe P, Colombo G.

Alcohol. 2013 Feb;47(1):69-73. doi: 10.1016/j.alcohol.2012.11.002. Epub 2012 Dec 6.

PMID:
23218664
8.

Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone.

Morairty SR, Revel FG, Malherbe P, Moreau JL, Valladao D, Wettstein JG, Kilduff TS, Borroni E.

PLoS One. 2012;7(7):e39131. doi: 10.1371/journal.pone.0039131. Epub 2012 Jul 2.

9.

Functional monoclonal antibody acts as a biased agonist by inducing internalization of metabotropic glutamate receptor 7.

Ullmer C, Zoffmann S, Bohrmann B, Matile H, Lindemann L, Flor P, Malherbe P.

Br J Pharmacol. 2012 Dec;167(7):1448-66. doi: 10.1111/j.1476-5381.2012.02090.x.

10.

Identification of a crucial amino acid in the helix position 6.51 of human tachykinin neurokinin 1 and 3 receptors contributing to the insurmountable mode of antagonism by dual NK₁/NK₃ antagonists.

Bissantz C, Bohnert C, Hoffmann T, Marcuz A, Schnider P, Malherbe P.

J Med Chem. 2012 Jun 14;55(11):5061-76. doi: 10.1021/jm2017072. Epub 2012 May 22.

PMID:
22574973
11.

G protein-coupled receptor transmembrane binding pockets and their applications in GPCR research and drug discovery: a survey.

Kratochwil NA, Gatti-McArthur S, Hoener MC, Lindemann L, Christ AD, Green LG, Guba W, Martin RE, Malherbe P, Porter RH, Slack JP, Winnig M, Dehmlow H, Grether U, Hertel C, Narquizian R, Panousis CG, Kolczewski S, Steward L.

Curr Top Med Chem. 2011;11(15):1902-24.

PMID:
21470172
12.

Tachykinin neurokinin 3 receptor antagonists: a patent review (2005 - 2010).

Malherbe P, Ballard TM, Ratni H.

Expert Opin Ther Pat. 2011 May;21(5):637-55. doi: 10.1517/13543776.2011.568482. Epub 2011 Mar 21. Review.

PMID:
21417773
13.

Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK₁ and NK₃ receptors.

Malherbe P, Knoflach F, Hernandez MC, Hoffmann T, Schnider P, Porter RH, Wettstein JG, Ballard TM, Spooren W, Steward L.

Br J Pharmacol. 2011 Feb;162(4):929-46. doi: 10.1111/j.1476-5381.2010.01096.x.

14.

Rational design of novel pyrrolidine derivatives as orally active neurokinin-3 receptor antagonists.

Ratni H, Ballard TM, Bissantz C, Hoffmann T, Jablonski P, Knoflach F, Knust H, Malherbe P, Nettekoven M, Patiny-Adam A, Riemer C, Schmitt M, Spooren W.

Bioorg Med Chem Lett. 2010 Nov 15;20(22):6735-8. doi: 10.1016/j.bmcl.2010.08.138. Epub 2010 Sep 17.

PMID:
20850972
16.

The positive allosteric modulator of the GABA(B) receptor, rac-BHFF, suppresses alcohol self-administration.

Maccioni P, Thomas AW, Carai MA, Gessa GL, Malherbe P, Colombo G.

Drug Alcohol Depend. 2010 Jun 1;109(1-3):96-103. doi: 10.1016/j.drugalcdep.2009.12.019. Epub 2010 Jan 20.

PMID:
20089372
17.

Identification of a critical residue in the transmembrane domain 2 of tachykinin neurokinin 3 receptor affecting the dissociation kinetics and antagonism mode of osanetant (SR 142801) and piperidine-based structures.

Malherbe P, Kratzeisen C, Marcuz A, Zenner MT, Nettekoven MH, Ratni H, Wettstein JG, Bissantz C.

J Med Chem. 2009 Nov 26;52(22):7103-12. doi: 10.1021/jm900948q.

PMID:
19817444
18.

Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor.

Malherbe P, Borroni E, Gobbi L, Knust H, Nettekoven M, Pinard E, Roche O, Rogers-Evans M, Wettstein JG, Moreau JL.

Br J Pharmacol. 2009 Apr;156(8):1326-41. doi: 10.1111/j.1476-5381.2009.00127.x.

19.

Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists.

Malherbe P, Borroni E, Pinard E, Wettstein JG, Knoflach F.

Mol Pharmacol. 2009 Sep;76(3):618-31. doi: 10.1124/mol.109.055152. Epub 2009 Jun 19.

PMID:
19542319
20.

Characterization of (R,S)-5,7-di-tert-butyl-3-hydroxy-3-trifluoromethyl-3H-benzofuran-2-one as a positive allosteric modulator of GABAB receptors.

Malherbe P, Masciadri R, Norcross RD, Knoflach F, Kratzeisen C, Zenner MT, Kolb Y, Marcuz A, Huwyler J, Nakagawa T, Porter RH, Thomas AW, Wettstein JG, Sleight AJ, Spooren W, Prinssen EP.

Br J Pharmacol. 2008 Jun;154(4):797-811. doi: 10.1038/bjp.2008.135. Epub 2008 Apr 21.

21.

Me-talnetant and osanetant interact within overlapping but not identical binding pockets in the human tachykinin neurokinin 3 receptor transmembrane domains.

Malherbe P, Bissantz C, Marcuz A, Kratzeisen C, Zenner MT, Wettstein JG, Ratni H, Riemer C, Spooren W.

Mol Pharmacol. 2008 Jun;73(6):1736-50. doi: 10.1124/mol.107.042754. Epub 2008 Feb 28.

PMID:
18308898
22.

BACE/APPV717F double-transgenic mice develop cerebral amyloidosis and inflammation.

Ozmen L, Woolley M, Albientz A, Miss MT, Nelboeck P, Malherbe P, Czech C, Gruninger-Leitch F, Brockhaus M, Ballard T, Jacobsen H.

Neurodegener Dis. 2005;2(6):284-98.

PMID:
16909011
23.

Comparison of the binding pockets of two chemically unrelated allosteric antagonists of the mGlu5 receptor and identification of crucial residues involved in the inverse agonism of MPEP.

Malherbe P, Kratochwil N, Mühlemann A, Zenner MT, Fischer C, Stahl M, Gerber PR, Jaeschke G, Porter RH.

J Neurochem. 2006 Jul;98(2):601-15.

24.

Determination of key amino acids implicated in the actions of allosteric modulation by 3,3'-difluorobenzaldazine on rat mGlu5 receptors.

Mühlemann A, Ward NA, Kratochwil N, Diener C, Fischer C, Stucki A, Jaeschke G, Malherbe P, Porter RH.

Eur J Pharmacol. 2006 Jan 4;529(1-3):95-104. Epub 2005 Dec 13.

PMID:
16352303
25.

An automated system for the analysis of G protein-coupled receptor transmembrane binding pockets: alignment, receptor-based pharmacophores, and their application.

Kratochwil NA, Malherbe P, Lindemann L, Ebeling M, Hoener MC, Mühlemann A, Porter RH, Stahl M, Gerber PR.

J Chem Inf Model. 2005 Sep-Oct;45(5):1324-36.

PMID:
16180909
26.

Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity.

Porter RH, Jaeschke G, Spooren W, Ballard TM, Büttelmann B, Kolczewski S, Peters JU, Prinssen E, Wichmann J, Vieira E, Mühlemann A, Gatti S, Mutel V, Malherbe P.

J Pharmacol Exp Ther. 2005 Nov;315(2):711-21. Epub 2005 Jul 22.

PMID:
16040814
27.

Opposite effects of Zn on the in vitro binding of [3H]LY354740 to recombinant and native metabotropic glutamate 2 and 3 receptors.

Malherbe P, Richards JG, Broger C, Zenner MT, Messer J, Kratzeisen C, Nakanishi S, Mutel V.

J Neurochem. 2005 Jul;94(1):150-60.

29.

[Blood transfusion safety: current progress].

Boyez E, Malherbe P, Tiry-Lescut C, Fontaine O.

Ann Biol Clin (Paris). 2004 Jul-Aug;62(4):462-4. French.

30.

[Curarization for contributing symptomatic treatment of myoclonic jerks induced by chloralose poisoning].

Boyez E, Malherbe P.

Ann Fr Anesth Reanim. 2004 Apr;23(4):361-3. French.

PMID:
15120781
31.

Identification of critical residues in the amino terminal domain of the human NR2B subunit involved in the RO 25-6981 binding pocket.

Malherbe P, Mutel V, Broger C, Perin-Dureau F, Kemp JA, Neyton J, Paoletti P, Kew JN.

J Pharmacol Exp Ther. 2003 Dec;307(3):897-905. Epub 2003 Oct 8.

PMID:
14534359
32.

PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation.

Richards JG, Higgins GA, Ouagazzal AM, Ozmen L, Kew JN, Bohrmann B, Malherbe P, Brockhaus M, Loetscher H, Czech C, Huber G, Bluethmann H, Jacobsen H, Kemp JA.

J Neurosci. 2003 Oct 1;23(26):8989-9003.

33.

Mutational analysis and molecular modeling of the binding pocket of the metabotropic glutamate 5 receptor negative modulator 2-methyl-6-(phenylethynyl)-pyridine.

Malherbe P, Kratochwil N, Zenner MT, Piussi J, Diener C, Kratzeisen C, Fischer C, Porter RH.

Mol Pharmacol. 2003 Oct;64(4):823-32.

PMID:
14500738
34.

Identification and characterization of a novel splice variant of the metabotropic glutamate receptor 5 gene in human hippocampus and cerebellum.

Malherbe P, Kew JN, Richards JG, Knoflach F, Kratzeisen C, Zenner MT, Faull RL, Kemp JA, Mutel V.

Brain Res Mol Brain Res. 2002 Dec 30;109(1-2):168-78.

PMID:
12531526
35.

Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glutamate 1 receptor.

Malherbe P, Kratochwil N, Knoflach F, Zenner MT, Kew JN, Kratzeisen C, Maerki HP, Adam G, Mutel V.

J Biol Chem. 2003 Mar 7;278(10):8340-7. Epub 2002 Dec 30.

36.

Pharmacological characterization of Ro 63-1908 (1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a novel subtype-selective N-methyl-D-aspartate antagonist.

Gill R, Alanine A, Bourson A, Buttelmann B, Fischer G, Heitz MP, Kew JN, Levet-Trafit B, Lorez HP, Malherbe P, Miss MT, Mutel V, Pinard E, Roever S, Schmitt M, Trube G, Wybrecht R, Wyler R, Kemp JA.

J Pharmacol Exp Ther. 2002 Sep;302(3):940-8.

PMID:
12183650
37.

Molecular cloning and functional characterization of human vesicular glutamate transporter 3.

Takamori S, Malherbe P, Broger C, Jahn R.

EMBO Rep. 2002 Aug;3(8):798-803. Epub 2002 Jul 15.

38.

Identification of essential residues involved in the glutamate binding pocket of the group II metabotropic glutamate receptor.

Malherbe P, Knoflach F, Broger C, Ohresser S, Kratzeisen C, Adam G, Stadler H, Kemp JA, Mutel V.

Mol Pharmacol. 2001 Nov;60(5):944-54.

PMID:
11641422
39.

Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site.

Knoflach F, Mutel V, Jolidon S, Kew JN, Malherbe P, Vieira E, Wichmann J, Kemp JA.

Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13402-7. Epub 2001 Oct 23. Erratum in: Proc Natl Acad Sci U S A 2001 Dec 18;98(26):15393.

40.

Pharmacological characterization of the novel nonpeptide orphanin FQ/nociceptin receptor agonist Ro 64-6198: rapid and reversible desensitization of the ORL1 receptor in vitro and lack of tolerance in vivo.

Dautzenberg FM, Wichmann J, Higelin J, Py-Lang G, Kratzeisen C, Malherbe P, Kilpatrick GJ, Jenck F.

J Pharmacol Exp Ther. 2001 Aug;298(2):812-9.

PMID:
11454946
41.

Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections.

Mutel V, Ellis GJ, Adam G, Chaboz S, Nilly A, Messer J, Bleuel Z, Metzler V, Malherbe P, Schlaeger EJ, Roughley BS, Faull RL, Richards JG.

J Neurochem. 2000 Dec;75(6):2590-601.

42.

Characterization of transgenic mice expressing apolipoprotein E4(C112R) and apolipoprotein E4(L28P; C112R).

Huber G, März W, Martin JR, Malherbe P, Richards JG, Sueoka N, Ohm T, Hoffmann MM.

Neuroscience. 2000;101(1):211-8.

PMID:
11068149
43.

Evidence that nicotinic alpha(7) receptors are not involved in the hyperlocomotor and rewarding effects of nicotine.

Grottick AJ, Trube G, Corrigall WA, Huwyler J, Malherbe P, Wyler R, Higgins GA.

J Pharmacol Exp Ther. 2000 Sep;294(3):1112-9.

PMID:
10945867
44.

Characterization of [(3)H]-LY354740 binding to rat mGlu2 and mGlu3 receptors expressed in CHO cells using semliki forest virus vectors.

Schweitzer C, Kratzeisen C, Adam G, Lundstrom K, Malherbe P, Ohresser S, Stadler H, Wichmann J, Woltering T, Mutel V.

Neuropharmacology. 2000 Jul 24;39(10):1700-6.

PMID:
10884552
45.
46.

Effect of the umami peptides on the ligand binding and function of rat mGlu4a receptor might implicate this receptor in the monosodium glutamate taste transduction.

Monastyrskaia K, Lundstrom K, Plahl D, Acuna G, Schweitzer C, Malherbe P, Mutel V.

Br J Pharmacol. 1999 Nov;128(5):1027-34.

47.
48.

Lazabemide for the treatment of Alzheimer's disease: rationale and therapeutic perspectives.

Cesura AM, Borroni E, Gottowik J, Kuhn C, Malherbe P, Martin J, Richards JG.

Adv Neurol. 1999;80:521-8. Review. No abstract available.

PMID:
10410766
49.

Cloning and functional expression of alternative spliced variants of the human metabotropic glutamate receptor 8.

Malherbe P, Kratzeisen C, Lundstrom K, Richards JG, Faull RL, Mutel V.

Brain Res Mol Brain Res. 1999 Apr 20;67(2):201-10.

PMID:
10216218
50.

cDNA cloning and molecular characterization of human brain metalloprotease MP100: a beta-secretase candidate?

Huber G, Thompson A, Grüninger F, Mechler H, Hochstrasser R, Hauri HP, Malherbe P.

J Neurochem. 1999 Mar;72(3):1215-23.

Supplemental Content

Loading ...
Support Center